Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase IIa Exploratory Clinical Trial to Evaluate the Efficacy and Safety of SC Administration of GV1001 0.56 or 1.12 Mg/day in Patients with PSP

Next Previous
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase IIa Exploratory Clinical Trial to Evaluate the Efficacy and Safety of SC Administration of GV1001 0.56 or 1.12 Mg/day in Patients with PSP

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tertomotide (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Therapeutic Use
  • Sponsors GemVax & KAEL

    • Most Recent Events

    • 29 Oct 2024 Results presented in a GemVax & KAEL Media Release.
    • 29 Oct 2024 According to a GemVax & KAEL media release, topline results of a Phase 2a clinical trial of GV1001 were presented at "Neuro2024: The PSP and CBD International Research Symposium" in Toronto, Canada, at 4:45 p.m. local time on 24th October.
    • 23 Oct 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top